Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZ


Primary Symbol: T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Bullboard Posts
Comment by slagheapon Nov 24, 2015 7:44pm
131 Views
Post# 24322041

RE:ridiculous

RE:ridiculous It`s just a simple legal disclaimer clause. Management has no control over volume or share price. The float is tight. Controlled by a small group. Their profits are in their short position which was 50% today and the shorting has been that way for months although I don`t expect to see a $10-$20 trading range again. The volatility might be less but the sell high and buy low still applies. Volume was 26m and o/s is 6.9m.  It`s their game and their rules if you want to play. Longer term (like Dec.2016) the share price should be back at pre-financing levels of $50-$60 if the phase 3 is good.

Forget the analysts price targets - they are part of the financing.
Bullboard Posts